Soluble epoxide hydrolase inhibitors reduce the development of atherosclerosis in apolipoprotein E-knockout mouse model

Arzu Ulu, Benjamin B. Davis, Hsing Ju Tsai, In Hae Kim, Christophe Morisseau, Bora Inceoglu, Oliver Fiehn, Bruce D. Hammock, Robert H Weiss

Research output: Contribution to journalArticle

95 Citations (Scopus)

Abstract

To determine whether sEH inhibitors influence atherosclerotic lesion formation, we used an established murine model of accelerated atherogenesis, ApoE knockout (-/-) mice. The sEH inhibitor, 1-adamantan-3-(5-(2-(2-ethylethoxy) ethoxy)pentyl)urea (AEPU) was delivered in drinking water. All animals were fed an atherogenic diet while simultaneously infused with angiotensin II by osmotic minipump to induce atherosclerosis. In AEPU-treated animals, there was a 53% reduction in atherosclerotic lesions in the descending aortae as compared to control aortae. AEPU and its major metabolites were detected in the plasma of animals which received it. As expected from the inhibition of sEH, a significant increase in linoleic and arachidonic acid epoxides, as well as an increase in individual 11,12-EET/DHET and 14,15-EET/DHET ratios, were observed. The reduction in atherosclerotic lesion area was inversely correlated with 11,12- and 14,15- EET/DHET ratios, suggesting that the reduction corresponds to the inhibition of sEH. Our data suggest that orally-available sEH inhibitors may be useful in the treatment of patients with atherosclerotic cardiovascular disease.

Original languageEnglish (US)
Pages (from-to)314-323
Number of pages10
JournalJournal of Cardiovascular Pharmacology
Volume52
Issue number4
DOIs
StatePublished - Oct 2008

Fingerprint

Epoxide Hydrolases
Apolipoproteins E
Knockout Mice
Atherosclerosis
Atherogenic Diet
Epoxy Compounds
Linoleic Acid
Thoracic Aorta
Arachidonic Acid
Angiotensin II
Drinking Water
Aorta
Cardiovascular Diseases
14,15-epoxy-5,8,11-eicosatrienoic acid
14,15-dihydroxyeicosatrienoic acid
11,12-epoxy-5,8,14-eicosatrienoic acid
Therapeutics

Keywords

  • 1-adamantan-3-(5-(2-(2-ethylethoxy)ethoxy)pentyl) urea
  • Apo E knockout mice
  • Atherosclerosis
  • Epoxyeicosatrienoic acid
  • Soluble epoxide hydrolase

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Cite this

Soluble epoxide hydrolase inhibitors reduce the development of atherosclerosis in apolipoprotein E-knockout mouse model. / Ulu, Arzu; Davis, Benjamin B.; Tsai, Hsing Ju; Kim, In Hae; Morisseau, Christophe; Inceoglu, Bora; Fiehn, Oliver; Hammock, Bruce D.; Weiss, Robert H.

In: Journal of Cardiovascular Pharmacology, Vol. 52, No. 4, 10.2008, p. 314-323.

Research output: Contribution to journalArticle

Ulu, Arzu ; Davis, Benjamin B. ; Tsai, Hsing Ju ; Kim, In Hae ; Morisseau, Christophe ; Inceoglu, Bora ; Fiehn, Oliver ; Hammock, Bruce D. ; Weiss, Robert H. / Soluble epoxide hydrolase inhibitors reduce the development of atherosclerosis in apolipoprotein E-knockout mouse model. In: Journal of Cardiovascular Pharmacology. 2008 ; Vol. 52, No. 4. pp. 314-323.
@article{79897b9f895d4e8e8aa2a462bb88f6a9,
title = "Soluble epoxide hydrolase inhibitors reduce the development of atherosclerosis in apolipoprotein E-knockout mouse model",
abstract = "To determine whether sEH inhibitors influence atherosclerotic lesion formation, we used an established murine model of accelerated atherogenesis, ApoE knockout (-/-) mice. The sEH inhibitor, 1-adamantan-3-(5-(2-(2-ethylethoxy) ethoxy)pentyl)urea (AEPU) was delivered in drinking water. All animals were fed an atherogenic diet while simultaneously infused with angiotensin II by osmotic minipump to induce atherosclerosis. In AEPU-treated animals, there was a 53{\%} reduction in atherosclerotic lesions in the descending aortae as compared to control aortae. AEPU and its major metabolites were detected in the plasma of animals which received it. As expected from the inhibition of sEH, a significant increase in linoleic and arachidonic acid epoxides, as well as an increase in individual 11,12-EET/DHET and 14,15-EET/DHET ratios, were observed. The reduction in atherosclerotic lesion area was inversely correlated with 11,12- and 14,15- EET/DHET ratios, suggesting that the reduction corresponds to the inhibition of sEH. Our data suggest that orally-available sEH inhibitors may be useful in the treatment of patients with atherosclerotic cardiovascular disease.",
keywords = "1-adamantan-3-(5-(2-(2-ethylethoxy)ethoxy)pentyl) urea, Apo E knockout mice, Atherosclerosis, Epoxyeicosatrienoic acid, Soluble epoxide hydrolase",
author = "Arzu Ulu and Davis, {Benjamin B.} and Tsai, {Hsing Ju} and Kim, {In Hae} and Christophe Morisseau and Bora Inceoglu and Oliver Fiehn and Hammock, {Bruce D.} and Weiss, {Robert H}",
year = "2008",
month = "10",
doi = "10.1097/FJC.0b013e318185fa3c",
language = "English (US)",
volume = "52",
pages = "314--323",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Soluble epoxide hydrolase inhibitors reduce the development of atherosclerosis in apolipoprotein E-knockout mouse model

AU - Ulu, Arzu

AU - Davis, Benjamin B.

AU - Tsai, Hsing Ju

AU - Kim, In Hae

AU - Morisseau, Christophe

AU - Inceoglu, Bora

AU - Fiehn, Oliver

AU - Hammock, Bruce D.

AU - Weiss, Robert H

PY - 2008/10

Y1 - 2008/10

N2 - To determine whether sEH inhibitors influence atherosclerotic lesion formation, we used an established murine model of accelerated atherogenesis, ApoE knockout (-/-) mice. The sEH inhibitor, 1-adamantan-3-(5-(2-(2-ethylethoxy) ethoxy)pentyl)urea (AEPU) was delivered in drinking water. All animals were fed an atherogenic diet while simultaneously infused with angiotensin II by osmotic minipump to induce atherosclerosis. In AEPU-treated animals, there was a 53% reduction in atherosclerotic lesions in the descending aortae as compared to control aortae. AEPU and its major metabolites were detected in the plasma of animals which received it. As expected from the inhibition of sEH, a significant increase in linoleic and arachidonic acid epoxides, as well as an increase in individual 11,12-EET/DHET and 14,15-EET/DHET ratios, were observed. The reduction in atherosclerotic lesion area was inversely correlated with 11,12- and 14,15- EET/DHET ratios, suggesting that the reduction corresponds to the inhibition of sEH. Our data suggest that orally-available sEH inhibitors may be useful in the treatment of patients with atherosclerotic cardiovascular disease.

AB - To determine whether sEH inhibitors influence atherosclerotic lesion formation, we used an established murine model of accelerated atherogenesis, ApoE knockout (-/-) mice. The sEH inhibitor, 1-adamantan-3-(5-(2-(2-ethylethoxy) ethoxy)pentyl)urea (AEPU) was delivered in drinking water. All animals were fed an atherogenic diet while simultaneously infused with angiotensin II by osmotic minipump to induce atherosclerosis. In AEPU-treated animals, there was a 53% reduction in atherosclerotic lesions in the descending aortae as compared to control aortae. AEPU and its major metabolites were detected in the plasma of animals which received it. As expected from the inhibition of sEH, a significant increase in linoleic and arachidonic acid epoxides, as well as an increase in individual 11,12-EET/DHET and 14,15-EET/DHET ratios, were observed. The reduction in atherosclerotic lesion area was inversely correlated with 11,12- and 14,15- EET/DHET ratios, suggesting that the reduction corresponds to the inhibition of sEH. Our data suggest that orally-available sEH inhibitors may be useful in the treatment of patients with atherosclerotic cardiovascular disease.

KW - 1-adamantan-3-(5-(2-(2-ethylethoxy)ethoxy)pentyl) urea

KW - Apo E knockout mice

KW - Atherosclerosis

KW - Epoxyeicosatrienoic acid

KW - Soluble epoxide hydrolase

UR - http://www.scopus.com/inward/record.url?scp=58149350130&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149350130&partnerID=8YFLogxK

U2 - 10.1097/FJC.0b013e318185fa3c

DO - 10.1097/FJC.0b013e318185fa3c

M3 - Article

VL - 52

SP - 314

EP - 323

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - 4

ER -